Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
sPLA2 Inhibitor · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| sPLA2 Inhibitor | DRUG | - |
Inclusion Criteria: Patients must * show evidence of acute infection * meet specified time windows * be 18 years of age or older Exclusion Criteria: Patients must not * have low white blood cell count * have undergone certain organ transplants * be HIV positive * be pregnant or breast feeding * h...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| ImmunityBio Inc | IBRX | 1 | PHASE2 | Nogapendekin alfa inbakicept |
| Bluejay Diagnostics, Inc. | BJDX | 2 | - | Undisclosed |
| CytoSorbents Corporation | CTSO | 1 | - | Undisclosed |
| Danaher Corporation | DHR | 3 | - | Undisclosed |
| Spectral AI, Inc. Class A | MDAI | 1 | N/A | Undisclosed |
sPLA2 Inhibitor is an investigational small molecule being developed for the treatment of sepsis, a life-threatening condition caused by the body's response to an infection. It is currently in Phase 1 clinical development, meaning it is still being tested for safety and efficacy and has not been approved for use.
sPLA2 Inhibitor is being developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's potential in treating patients with sepsis.
sPLA2 Inhibitor is in Phase 1 of clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for its safety and potential efficacy in patients with severe sepsis.
sPLA2 Inhibitor has been studied in one clinical trial, identified as NCT00034476. This was a Phase IIb study that evaluated the efficacy and safety of the drug in patients with severe sepsis. The trial, which enrolled 466 participants, has been completed and was conducted in the United States, Belgium, Hungary, Netherlands, and Poland.
No, sPLA2 Inhibitor is not FDA approved. It is an investigational drug currently in Phase 1 of clinical development. The drug has been studied in a completed clinical trial for sepsis, but it has not received approval from the U.S. Food and Drug Administration or any other regulatory agency.